CN109890391B - 痴呆症的治疗 - Google Patents

痴呆症的治疗 Download PDF

Info

Publication number
CN109890391B
CN109890391B CN201780067154.4A CN201780067154A CN109890391B CN 109890391 B CN109890391 B CN 109890391B CN 201780067154 A CN201780067154 A CN 201780067154A CN 109890391 B CN109890391 B CN 109890391B
Authority
CN
China
Prior art keywords
compound
acid
treatment
neurotransmission
ftld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780067154.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109890391A (zh
Inventor
C·M·威谢克
B·O·舍尔特
D·J·威谢克
J·M·D·斯托里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN109890391A publication Critical patent/CN109890391A/zh
Application granted granted Critical
Publication of CN109890391B publication Critical patent/CN109890391B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Valve Device For Special Equipments (AREA)
CN201780067154.4A 2016-09-01 2017-08-25 痴呆症的治疗 Active CN109890391B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614834.8 2016-09-01
GBGB1614834.8A GB201614834D0 (en) 2016-09-01 2016-09-01 Treatment of dementia
PCT/EP2017/071437 WO2018041739A1 (en) 2016-09-01 2017-08-25 Treatment of dementia

Publications (2)

Publication Number Publication Date
CN109890391A CN109890391A (zh) 2019-06-14
CN109890391B true CN109890391B (zh) 2023-01-31

Family

ID=57139937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780067154.4A Active CN109890391B (zh) 2016-09-01 2017-08-25 痴呆症的治疗

Country Status (17)

Country Link
US (1) US10842796B2 (https=)
EP (1) EP3506904B1 (https=)
JP (1) JP7066679B2 (https=)
KR (1) KR102559354B1 (https=)
CN (1) CN109890391B (https=)
AU (1) AU2017318333B2 (https=)
DK (1) DK3506904T3 (https=)
ES (1) ES2847929T3 (https=)
GB (1) GB201614834D0 (https=)
HR (1) HRP20210162T1 (https=)
MX (1) MX384442B (https=)
MY (1) MY187564A (https=)
PL (1) PL3506904T3 (https=)
PT (1) PT3506904T (https=)
SG (1) SG11201901125TA (https=)
SI (1) SI3506904T1 (https=)
WO (1) WO2018041739A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
KR102592614B1 (ko) 2016-07-25 2023-10-24 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
DK3826639T3 (da) * 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
WO2020048593A1 (en) 2018-09-05 2020-03-12 Wista Laboratories Ltd. Network methods for neurodegenerative diseases
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
JP2023524146A (ja) * 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド 低酸素血症の治療に使用されるメチルチオニニウム化合物
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4342451A1 (en) * 2022-09-22 2024-03-27 Galenicum Health SLU Pharmaceutical compositions and manufacturing methods thereof
US20240115579A1 (en) * 2022-09-22 2024-04-11 Galenicum Health S.L.U. Pharmaceutical compositions and manufacturing methods thereof
WO2024178120A2 (en) * 2023-02-21 2024-08-29 Prosetta Biosciences, Inc. Phenothiazinyl compounds and uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454009A (zh) * 2006-03-30 2009-06-10 神经激肽有限公司 (S)-roscovitine在预防和/或治疗神经疾病中的应用
CN101460222A (zh) * 2006-03-29 2009-06-17 维斯塔实验室有限公司 锍化合物及其用途
CN101883567A (zh) * 2007-10-03 2010-11-10 维斯塔实验室有限公司 二氨基吩噻嗪的治疗用途
CN102936244A (zh) * 2012-12-04 2013-02-20 合肥工业大学 一种他克林-吩噻嗪异二联体类化合物及其制备方法
CN103649061A (zh) * 2011-02-11 2014-03-19 维斯塔实验室有限公司 吩噻嗪二胺鎓盐和其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2003101458A1 (en) 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2005286235C1 (en) 2004-09-23 2013-08-22 TauRx Therapeutics Management Ltd Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC)
EP2013191B3 (en) * 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
CN101820884B (zh) 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
DK3378856T3 (da) 2009-09-24 2020-12-21 Wista Lab Ltd Krystallinske methylthioniniumchlorid-hydrater
PL2480540T3 (pl) 2009-09-24 2018-05-30 Wista Laboratories Ltd. Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460222A (zh) * 2006-03-29 2009-06-17 维斯塔实验室有限公司 锍化合物及其用途
CN101454009A (zh) * 2006-03-30 2009-06-10 神经激肽有限公司 (S)-roscovitine在预防和/或治疗神经疾病中的应用
CN101883567A (zh) * 2007-10-03 2010-11-10 维斯塔实验室有限公司 二氨基吩噻嗪的治疗用途
CN103649061A (zh) * 2011-02-11 2014-03-19 维斯塔实验室有限公司 吩噻嗪二胺鎓盐和其用途
CN102936244A (zh) * 2012-12-04 2013-02-20 合肥工业大学 一种他克林-吩噻嗪异二联体类化合物及其制备方法

Also Published As

Publication number Publication date
US20190192530A1 (en) 2019-06-27
KR20190045273A (ko) 2019-05-02
AU2017318333B2 (en) 2023-05-11
WO2018041739A1 (en) 2018-03-08
JP2019526571A (ja) 2019-09-19
US10842796B2 (en) 2020-11-24
SI3506904T1 (sl) 2021-03-31
SG11201901125TA (en) 2019-03-28
EP3506904B1 (en) 2020-12-09
PL3506904T3 (pl) 2021-07-26
HRP20210162T1 (hr) 2021-03-19
EP3506904A1 (en) 2019-07-10
CA3034625A1 (en) 2018-03-08
GB201614834D0 (en) 2016-10-19
MY187564A (en) 2021-09-30
CN109890391A (zh) 2019-06-14
MX384442B (es) 2025-03-14
AU2017318333A1 (en) 2019-04-18
KR102559354B1 (ko) 2023-07-26
MX2019002429A (es) 2019-07-08
DK3506904T3 (da) 2021-01-04
JP7066679B2 (ja) 2022-05-13
PT3506904T (pt) 2021-02-02
ES2847929T3 (es) 2021-08-04

Similar Documents

Publication Publication Date Title
CN109890391B (zh) 痴呆症的治疗
CA2671321A1 (en) Means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof
AU2016319107A1 (en) Methods of treating neurodegenerative disorders in a particular patient population
US20190247379A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN114096254A (zh) 作为认知功能的增强剂的白甲锍堇
CN104582793A (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
CA3034625C (en) Treatment of dementia
WO2022007982A2 (zh) 一种药物组合物及其应用
HK40003690A (en) Treatment of dementia
HK40003690B (en) Treatment of dementia
JP2025500088A (ja) Ｆｅｎｍ及びアセチルコリンエステラーゼ阻害剤をベースとする新規相乗的組合せ
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
JP2023544224A (ja) ヒト低コリン作動性障害の処置のための医薬の組合せ
CN114901282A (zh) 在痴呆患者中治疗行为和精神症状
CN116635034A (zh) 用于治疗人低胆碱能障碍的药物组合
CN111050761A (zh) 阿尔茨海默病的基于idalopirdine的组合治疗
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant